Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Using a Biomarker-Driven Approach in TNBC
December 20th 2021In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.
Early-Phase Targeted Agents Are Poised to Expand Armamentarium in HNSCC
September 23rd 2021The emergence of early-phase immune-oncology agents and their respective novel mechanisms of action in head and neck squamous cell carcinoma suggests a new standard of care in the metastatic first-line setting within the next 2 years.
Exploring CAR T-Cell Therapies in the Indolent Lymphoma Setting
September 10th 2021Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.
Adding LuPSMA to Standard Treatment Extends OS, Delays Disease Progression in mCRPC
August 15th 2021Adding the targeted radioligand LuPSMA to standard of care therapy for patients with metastatic castration resistant prostate cancer after androgen receptor pathway inhibition and chemotherapy extended overall survival and delayed disease progression
Clinical Trial Matching Service in Hematologic Cancers Mitigates Barriers to Enrollment
July 18th 2021A national, telephone-based nurse navigator-led service model that aimed to reduce barriers to clinical trial participation among patients with a blood cancer and identified patient demographic and clinical characteristics associated with enrollment was shown to mitigate modifiable barriers to trial enrollment.
Smart Watch Used for Biometric Measuring Demonstrates Positive Response, Overall Satisfaction
June 26th 2021Investigators anticipate that improved versions of the application will evolve over the phases as patient-specific queries are optimized and as cancer-specific pathways are incorporated. A multidisciplinary team will provide a tailored and integrative approach, concluded the investigators.
ODAC Panel Approves 4 of 6 Anti–PD-1/PD-L1 Drugs in Accelerated Approval Program
June 16th 2021An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma
June 14th 2021Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.